New hope for Hard-to-Treat cancers: targeted pill aims to stop tumor growth

NCT ID NCT03310879

Recruiting now Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a drug called abemaciclib in people with advanced solid tumors that have specific changes in cyclin or CDK genes. The drug works by blocking proteins that help cancer cells grow. Researchers want to see if it can stop or slow the cancer for at least 4 months. About 38 participants will take the pill and be monitored for side effects and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abemaciclib
What this could lead to: If it works, this could point toward a targeted treatment for certain hard-to-treat cancers with specific genetic changes.
What could go wrong: This is a small, early-phase trial with only 38 participants, so results may not apply broadly. The drug may not shrink tumors or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER

Contacts and locations

Locations

Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.